depatuxizumab mafodotin

a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead

Also Known As:

ABBV-221; L-Valinamide, N-(6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1S,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidi nyl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl; N-(6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)-N-methyl-L-valyl-N-((3R,4S,5S)-1-((2S)-2-((1S,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-3-methoxy-5-methyl-1-oxo-4-heptanyl)-N-methyl-L-valinamide; depatux-m

Networked: 28 relevant articles (8 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gan, Hui K: 7 articles (01/2021 - 12/2017)
2.	Scott, Andrew M: 7 articles (01/2021 - 12/2017)
3.	Xiong, Hao: 5 articles (12/2021 - 12/2017)
4.	Eoli, Marica: 5 articles (08/2021 - 01/2020)
5.	Reilly, Edward B: 5 articles (04/2021 - 01/2018)
6.	Franceschi, Enrico: 4 articles (08/2021 - 01/2020)
7.	Golfinopoulos, Vassilis: 4 articles (08/2021 - 01/2020)
8.	Gorlia, Thierry: 4 articles (08/2021 - 01/2020)
9.	Looman, Jim: 4 articles (08/2021 - 01/2020)
10.	Weller, Michael: 4 articles (08/2021 - 01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "This phase 1/2 study evaluated the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors with known wild-type EGFR overexpression, amplification, or mutated EGFR variant III. A 3 + 3 dose escalation was used, and 2 dosing schedules were evaluated. " 12/01/2021 - "Poor efficacy in orthotopic PDXs was associated with limited and heterogeneous distribution of Depatux-M into tumor tissues, and artificial disruption of the BBB or bypass of the BBB by direct intracranial injection of Depatux-M into orthotopic tumors markedly enhanced the efficacy of drug treatment. " 01/01/2021 - "Both preclinical and clinical data showed intra-tumoral concentration and efficacy of Depatux-m inversely correlated with tumor size. " 12/01/2021 - "In contrast to the profound benefit observed in heterotopic tumors, only two of seven intrinsically sensitive PDXs were responsive to Depatux-M as intracranial tumors. " 01/01/2018 - "Based on these results, ABBV-221 has advanced to a phase I clinical trial in patients with advanced solid tumors associated with elevated levels of EGFR. "
2.	Glioblastoma (Glioblastoma Multiforme) 12/01/2017 - "Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study." 01/01/2023 - "However, depatuxizumab mafodotin, an ADC targeting wild-type EGFR and EGFR variant III, did not provide a definitive overall survival benefit in patients with newly diagnosed or recurrent EGFR-amplified glioblastoma in phase II and III trials, despite objective radiological responses in some patients. " 01/01/2021 - "Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma." 01/01/2018 - "Depatux-m has demonstrated promising clinical activity in glioblastoma multiforme (GBM) patients and is currently being evaluated in clinical trials in first-line and recurrent GBM disease settings. " 01/01/2023 - "Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial."
3.	Glioma (Gliomas) 12/01/2021 - "Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial." 12/01/2021 - "In first-line arms, patients with newly diagnosed WHO grade III/IV glioma received Depatux-M plus chemoradiotherapy. " 12/01/2021 - "This study showed acceptable safety profile of Depatux-M alone or plus chemotherapy/chemoradiotherapy in Japanese patients with WHO grade III/IV glioma. " 01/01/2020 - "Depatux-M and temozolomide in advanced high-grade glioma." 12/01/2021 - "In second-line arms, patients with EGFR-amplified recurrent WHO grade III/IV glioma received Depatux-M plus chemotherapy (temozolomide) or Depatux-M alone regardless of EGFR status. "
4.	Hypersensitivity (Allergy) 01/01/2020 - "Ligand hypersensitivity can explain the therapeutic efficacy of depatux-m as increased ligand-induced activation will result in increased exposure of the epitope to the antibody-drug conjugate. "
5.	Gliosarcoma 05/31/2023 - "The study enrolled adult patients with epidermal growth factor receptor-amplified, histologically confirmed, newly diagnosed supratentorial glioblastoma or grade IV gliosarcoma, and a Karnofsky Performance Status ≥70, receiving depatuxizumab mafodotin. "

Related Drugs and Biologics

1.	depatuxizumab mafodotin
2.	Temozolomide (Temodar)
3.	Immunoconjugates (Immunoconjugate)
4.	Epitopes
5.	Nucleotides
6.	Ligands
7.	ErbB Receptors (EGF Receptor)
8.	Lomustine (CCNU)
9.	Zirconium-89
10.	monomethylauristatin F

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Chemoradiotherapy

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page